German drug wholesaler Gehe AG reported a 34% improvement in first-half 1995 pretax profits, which reached 151 million Deutschemarks ($105.2 million).
The company said that group sales for the period were "considerably influenced" by the acquisition in April of UK drug wholesaler AAH Holdings (which it acquired through a hostile bid; Marketletters passim), without which turnover would have increased only 8.5%. For the year as a whole, Gehe expects total turnover to reach 18.5 billion marks ($12.89 billion), which would be an increase of around 22% on the 1994 level of 15.2 billion marks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze